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1135-73 Socioeconomic Status and Outcomes of Elderly 
Patients Hospitalized With Heart Failure
Saif S. Rathore, Frederick A. Masoudi, Yongfei Wang, JoAnne M. Foody, Jeptha P. Curtis, 
Edward P. Havranek, Harlan M. Krumholz, Yale University School of Medicine, New 
Haven, CT, Colorado Foundation for Medical Care, Aurora, CO
Background: Prior studies suggest that patients with lower socioeconomic status (SES)
experience poorer health outcomes. We sought to determine whether patient SES was
related to readmission and mortality in a national cohort of community-based elderly
patients hospitalized for heart failure.
Methods: We used data from the National Heart Failure Project, a Centers for Medicare
& Medicaid Services sample of Medicare beneficiaries hospitalized nationwide with a
principal diagnosis of heart failure between 1998 and 1999. Analysis was restricted to
patients age >65 years presenting with heart failure (n=25,086). Patient SES was deter-
mined using a US Census-derived measure reflecting household income, education,
occupation, and home value based on the patient’s ZIP code of residence. ZIP codes
were divided into four groups reflecting their relative SES (SES1 – lowest SES; SES4 –
highest SES). Multivariable hierarchical logistic regression analyses were conducted to
assess the association between SES and outcomes (30-day and one-year mortality and
one-year readmission) adjusting for other patient and provider characteristics.
Results: There were no SES-associated differences in crude mortality at 30 days (SES1
8.1%, SES2 8.3%, SES3 8.6%, SES4 8.7%, P=0.92) or at one-year (SES1 33.5%, SES2
36.1%, SES3 35.7%, SES4 36.1%, P=0.23). The adjusted relative risks of 30-day mortal-
ity remained comparable in all SES groups (SES1 1.13, 95% CI 0.92-1.38; SES2 1.03,
95% CI 0.87-1.22; SES3 1.01, 95% CI 0.85-1.20; SES4 1.00, referent). However,
patients of lower SES had a higher adjusted relative risk of mortality at one year (SES1
1.10, 95% CI 1.02-1.19; SES2 1.12, 95% CI 1.05-1.18; SES3 1.04, 95% CI 0.97-1.11;
SES4, referent). Lower SES patients also had higher crude one year readmission rates
(SES1 71.8%, SES2 67.7%, SES3 67.4%, SES4 65.8%, P=0.003), which persisted after
multivariable adjustment (SES1 1.08, 1.03-1.12; SES2 1.01, 0.98-1.05; SES3 1.02, 0.98-
1.05; SES4 1.00, referent).
Conclusion: Although not associated with short-term outcomes, lower SES may confer
an increased long-term risk for mortality and re-hospitalization in elderly patients hospi-
talized with heart failure.
1135-74 Survival Differences Between Hispanic and Non-
Hispanic Patients With Cardiovascular Disease 
Initiating Renal Replacement Therapy in the United 
States
Cezar A. Iliescu, Bhamidipati V.R. Murthy, Francisco Fuentes, Austin G. Stack, The 
University of Texas Health Science Center, Houston, TX
Background: The survival advantage of Hispanic patients with cardiovascular (CV) dis-
ease is well known in the general U.S. population. Whether the same is true for Hispanic
patients who reach end-stage kidney disease (ESKD) is unknown.
Methods: We explored survival differences between Hispanic and Non-Hispanic patients
new to dialysis with known CV disease (coronary artery disease [CAD], peripheral vascu-
lar disease [PVD] and stroke [CVA]) in a national cohort. Patients were initiated on dialy-
sis between 5/1995-12/2000 and followed until 12/2001 using the U.S. Renal Data
System. Cox proportional hazards regression evaluated mortality risks with adjustment
for sociodemographic characteristics and 18 comorbid indicators recorded at baseline.
The cohort was stratified by diabetes.
Results: Overall, the prevalence of CAD, PVD and CVA was significantly lower in His-
panics compared to non-Hispanics. The prevalence estimates and adjusted relative haz-
ards (RR) for death for Hispanic vs non-Hispanic patients are shown in the table. 
**P<0.001, ***P<0.0001.
Conclusions: The survival of Hispanic patients with known CV disease who receive
renal replacement therapy in the United States is substantially greater than that of non-
Hispanic patients. This benefit predominantly seen in patients with diabetes mellitus is
not explained by baseline differences in measurable comorbidity.
1135-75 Is Smoking as Important a Risk Factor for Coronary 
Heart Disease in Asia as It Is in Primarily Caucasian 
Populations?
Mark Woodward, Dongfeng Gu, Il Suh, Federica Barzi, for the Asia Pacific Cohort 
Studies Collaboration, Institute for International Health, Sydney, Australia
Background: It is now almost universally recognised that smoking is a leading cause of
coronary heart disease (CHD). However, most previous research has been carried out in
the West, and many researchers believe that the risk from smoking is less amongst
Asians. Partially as a consequence of this, smoking rates amongst men are extremely
high in Asian countries, exceeding 70% in some instances. We sought to address this
issue by assembling the largest medical database to date from the Asia-Pacific region,
collecting data from 42 cohort studies, providing an opportunity to accurately compare
the effect of smoking habit on fatal CHD between Asian and Australasian (primarily Cau-
casian) populations.
Methods: Smoking status, defined as either current smoking or not at baseline, was
recorded for over half a million participants (over 80% from Asia) aged 20y and over, fol-
lowed-up for an average of 6.8 years. Cox models, stratified by cohort and sex and
adjusted for age-at-risk and systolic blood pressure, were used to estimate the hazard
ratios (HR) and 95% confidence intervals (CI) for fatal CHD for smokers compared to
non-smokers. Further adjustments were made for total cholesterol, for which there were
many missing values.
Results: For age-at-risk 20-65y, smoking increased the risk of fatal CHD two-fold (HR:
2.02, 95%CI: 1.73-2.35). The relative risk was higher for Australasian populations (HR:
2.58, 95%CI: 2.07-3.22) than Asian (HR: 1.64, 95% CI: 1.34-2.00) (p for homogene-
ity=0.003). Relative risk declined with age. Corresponding results for age groups 65-75y
and over 75y showed similar regional differentials, although not significantly different by
region (p>0.30). Adjustment for cholesterol had no substantive effect on estimates.
Conclusions: Smoking is a strong independent risk factor for fatal CHD, particularly for
relatively young people, in both Asian and Australasian populations. Although the age-
specific relative risks are lower in Asia, possibly due to a less “mature” smoking epi-
demic, better tobacco control would still be expected to alleviate a substantial proportion
of the increasing burden of CHD in Asia.
1135-76 Racial Variations in Treatment and Outcomes of African 
American and White Patients With Non ST-Elevation 
Acute Coronary Syndromes: Insights From CRUSADE
Ali F. Sonel, Chester B. Good, Jyotsna Mulgand, Matthew T. Roe, W. Brian Gibler, Sidney 
C. Smith, Jr., Mauricio G. Cohen, Robert Zalenski, Charles V. Pollack, Jr., E. Magnus 
Ohman, Eric D. Peterson, Center for Health Equity Research and Promotion, Pittsburgh, 
PA, Duke Clinical Research Institute, Durham, NC
Background: African American (AA) patients with non–ST-segment elevation (NSTE)
acute coronary syndromes (ACS) are less likely than white patients to receive coronary
interventions. It is unknown whether racial disparities exist for other treatments for NSTE
ACS and how different treatment approaches affect outcomes.
Methods: The CRUSADE Initiative included 5,504 AAs and 37,813 whites with high-risk
ACS (ST depression or positive cardiac markers). We compared the use of Guideline-
recommended therapies and outcomes between AA and white patients, adjusting for
demographic, clinical, and hospital factors; insurance coverage; and access to cardiolo-
gists.
Results: AA patients were younger and more likely to have hypertension, diabetes, heart
failure, and renal insufficiency, but less likely to have HMO/private insurance coverage,
prior revascularization, hypercholesterolemia, or primary cardiology care. AA patients
were more likely to receive aspirin and at least as likely to receive beta blockers, but sig-
nificantly less likely to receive GP IIb-IIIa inhibitors, clopidogrel, catheterization, or revas-
cularization procedures (Table). Nonetheless, risk-adjusted outcomes were similar
between AA and white patients.
Conclusions: AA patients with NSTE ACS are significantly less likely than whites to
receive medical and invasive therapy. Longitudinal studies are needed to assess the
long-term impact of racial disparities in ACS treatment.
Group CAD PVD CVA
%RR %RR %RR
Diabetic(N=134,722)
Non-Hispanic (32.6)1.00 (19.5)1.00 (11.1)1.00
Hispanic (25.1)0.74*** (16.8)0.70*** (7.7)0.71***
Non-Diabetic (N=127,783)
Non-Hispanic (21.4)1.00 (10.3)1.00 (7.7)1.00
Hispanic (12.2)0.87** (5.5) 0.91 (4.5)0.88
Selected Treatment Variables and Outcomes
White (%)
(n=37,813)
AA (%)
(n=5,504)
Adjusted OR 95% CI
Acute Medications (within 24h)
Aspirin 90.9 92.0 1.23 1.09–1.39
Beta blocker 77.8 76.5 1.00 0.92–1.10
GP IIb-IIIa inhibitor 35.7 29.2 0.80 0.74–0.87
Clopidogrel 40.6 32.1 0.83 0.77–0.90
Heparin, any 83.1 78.0 0.90 0.81–1.00
Invasive Management
Cardiac cath (<48 hours) 47.3 35.5 0.73 0.67–0.79
PCI 38.0 26.4 0.72 0.67–0.78
CABG 12.1 8.1 0.74 0.65–0.83
In-Hospital Events
Death 4.9 4.7 1.02 0.87–1.20
Death/MI 7.71 6.52 0.92 0.81–1.05
